Review of Diagnostic and Therapeutic Approach to Canine Myxomatous Mitral Valve Disease

Menciotti, Giulio; Borgarelli, Michele

doi:10.3390/vetsci4040047

Cited by 19 publications

(25 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The therapeutic protocol applied was clearly reported on the clinical record from the first to the last examiner, as well as whether the owner was willing to be interviewed by telephone. In this study all genders, weights and breeds were included, except for Cavalier King Charles Spaniel [8,20,21]. The clinical records of subjects for whom cardioactive therapy had previously been set up were also included.…”

Section: Methodsmentioning

confidence: 99%

“…The aim of DMVD treatment is to modulate hemodynamic and neurohormonal disorders, including high venous pressures, reduce the systolic function, activate the sympathetic and renin-angiotensin-aldosterone systems, and also release cytokines and vasopressin [1,2]. Treatment of CHF due to DMVD consists of a diuretic (loop diuretic, ++ furosemide) and additional agents (angiotensin-converting enzyme inhibitors, inodilators and aldosterone receptor antagonists) [8,9]. Angiotensin-converting enzyme inhibitors (ACE-Is), benazepril or enalapril, combined with furosemide improve the quality of life [4,10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols

Bagardi

Locatelli

Zanaboni

et al. 2020

Preprint

View full text Add to dashboard Cite

28 Clinical records of dogs with spontaneous degenerative mitral valve disease (DMVD) with 29 clinical signs related to congestive heart failure (CHF) that had been recruited during routine 30 clinical practice, between 2001 and 2018 at the Cardiology Unit of the Veterinary Teaching 31 Hospital (University of Milan) were included in this retrospective cohort study. Baseline 32 echocardiographic data were evaluated. Median survival times (MSTs) were calculated. Data 33 on therapeutic treatment, ISACHC or ACVIM classes were reviewed based on the inclusion 34 period and type of endpoint (i.e. cardiac death or death for other causes). The main goal of 35 this data review was to retrospectively evaluate 259 clinical records of subjects belonging to 36

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols

Bagardi

Locatelli

Zanaboni

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Myxomatous mitral valve disease (MMVD) is the most common acquired cardiovascular disease in dogs, and accounts for approximately 75% of cases of chronic heart failure [6][7][8][9]. The etiology of the myxomatous process is still unknown [10]. Myxomatous mitral valves are characterized by a disorganization of the structural elements of the leaflets and a weakening of the Chordae tendineae as well.…”

Section: Introductionmentioning

confidence: 99%

Biomechanical–Structural Correlation of Chordae tendineae in Animal Models: A Pilot Study

Gach

Janus

Mackiewicz

et al. 2021

Animals

View full text Add to dashboard Cite

The mitral valve apparatus is a complex structure consisting of the mitral ring, valve leaflets, papillary muscles and chordae tendineae (CT). The latter are mainly responsible for the mechanical functions of the valve. Our study included investigations of the biomechanical and structural properties of CT collected from canine and porcine hearts, as there are no studies about these properties of canine CT. We performed a static uniaxial tensile test on CT samples and a histopathological analysis in order to examine their microstructure. The results were analyzed to clarify whether the changes in mechanical persistence of chordae tendineae are combined with the alterations in their structure. This study offers clinical insight for future research, allowing for an understanding of the process of chordae tendineae rupture that happens during degenerative mitral valve disease—the most common heart disease in dogs.

show abstract

“…Myxomatous mitral valve disease (MMVD) is the most common cardiac disease in dogs, primarily affecting small breeds ( 1 ). The standard care for this disease is primarily medical therapy, while surgical treatment is performed in a minority of dogs ( 2 ). Medical therapy postpones the onset of congestive heart failure (CHF), and also increases the survival time once CHF develops ( 3 – 6 ).…”

Section: Introductionmentioning

confidence: 99%

Preliminary Outcome of a Novel Edge-to-Edge Closure Device to Manage Mitral Regurgitation in Dogs

et al. 2020

View full text Add to dashboard Cite

Background: Veterinary management of mitral valve regurgitation due to mxyomatous valve disease in dogs is limited to medical treatments, which only postpones the onset of congestive heart failure or alleviates clinical symptoms. Most surgical procedures to manage this condition in humans require cardiopulmonary bypass and have a high risk of complications.Animals: Eight dogs with naturally occurring mitral valve regurgitation.Methods: Prospective observational study. All dogs were treated with a novel edge-to-edge transcatheter device named ValveClamp. The total surgical procedural time and total catheterization time were recorded. Echocardiographic variables measured pre- and post-procedure were compared using Wilcoxin-signed rank test with a P < 0.05 considered significant. Data were expressed as median and interquartile range and absolute numbers and percentages.Results: The procedural success rate was 100% and all the dogs survived without complications. The median (interquartile range) total surgical procedural time was 86.5 (76–96.2) minutes and catheterization time was 23.5 (22–33.8) minutes. Echocardiography revealed a significant reduction in mitral regurgitation severity in all dogs following the procedure based on both a reduced mitral regurgitant maximum jet area (P = 0.012) and a reduced mitral regurgitant maximum jet area to left atrial area (P = 0.018).Conclusion: The ValveClamp device is effective at reducing the severity of mitral regurgitation in dogs with naturally occurring myxomatous valve disease.

show abstract

Review of Diagnostic and Therapeutic Approach to Canine Myxomatous Mitral Valve Disease

Abstract: Abstract:The most common heart disease that affects dogs is myxomatous mitral valve disease. In this article, we review the current diagnostic and therapeutic approaches to this disease, and we also present some of the latest technological advancements in this field.

Cited by 19 publications

References 122 publications

Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols

Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols

Biomechanical–Structural Correlation of Chordae tendineae in Animal Models: A Pilot Study

Preliminary Outcome of a Novel Edge-to-Edge Closure Device to Manage Mitral Regurgitation in Dogs

Contact Info

Product

Resources

About